Tailoring inorganic nanoadjuvants towards next-generation vaccines.
暂无分享,去创建一个
Atsuo Ito | Xia Li | Xiupeng Wang | A. Ito | Xiupeng Wang | Xia Li
[1] Y. Hayashi,et al. An immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis, Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice. , 1999, Immunology letters.
[2] D. Tambourgi,et al. Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. , 2010, Vaccine.
[3] Dean Ho,et al. Cancer Nanomedicine: From Drug Delivery to Imaging , 2013, Science Translational Medicine.
[4] Paul Richman,et al. Aluminum salts in vaccines--US perspective. , 2002, Vaccine.
[5] Gerd Ritter,et al. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. , 2008, ACS nano.
[6] S. Kanoni,et al. In vitro and in vivo effects of zinc on cytokine signalling in human T cells , 2008, Experimental Gerontology.
[7] J. Buer,et al. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. , 2010, Biomaterials.
[8] N. Mitter,et al. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. , 2013, Small.
[9] C. Hunter,et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.
[10] R. Serda. Particle platforms for cancer immunotherapy , 2013, International journal of nanomedicine.
[11] Jayanth Panyam,et al. Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.
[12] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[13] S. Samman,et al. Zinc and Regulation of Inflammatory Cytokines: Implications for Cardiometabolic Disease , 2012, Nutrients.
[14] M. J. Sawkins,et al. The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation , 2017, Scientific Reports.
[15] Zhengrong Cui,et al. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.
[16] R. Flavell,et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy , 2011, Proceedings of the National Academy of Sciences.
[17] Bengt Fadeel,et al. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. , 2011, Toxicology and applied pharmacology.
[18] C. Zhi,et al. Identification of a boron nitride nanosphere-binding peptide for the intracellular delivery of CpG oligodeoxynucleotides. , 2012, Nanoscale.
[19] Marco Zanella,et al. Biological applications of gold nanoparticles. , 2008, Chemical Society reviews.
[20] Jun Lin,et al. Functionalized mesoporous silica materials for controlled drug delivery. , 2012, Chemical Society reviews.
[21] J. Brewer,et al. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro , 2012, Immunology letters.
[22] Rajesh K. Gupta,et al. Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.
[23] Jianlin Shi,et al. One-pot synthesis of magnetic and mesoporous bioactive glass composites and their sustained drug release property , 2008 .
[24] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[25] V. Kanchan,et al. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. , 2007, Biomaterials.
[26] C. Fan,et al. Polyvalent immunostimulatory nanoagents with self-assembled CpG oligonucleotide-conjugated gold nanoparticles. , 2012, Angewandte Chemie.
[27] A. Verma,et al. Zinc oxide nanoparticles provide an adjuvant effect to ovalbumin via a Th2 response in Balb/c mice. , 2014, International immunology.
[28] Richard A Flavell,et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.
[29] S. Gabrielsson,et al. Mesoporous silica particles potentiate antigen-specific T-cell responses. , 2014, Nanomedicine.
[30] Xuebin Wang,et al. Multimodal luminescent-magnetic boron nitride nanotubes@NaGdF₄:Eu structures for cancer therapy. , 2014, Chemical communications.
[31] E. Relyveld,et al. Calcium phosphate adjuvanted allergens. , 1985, Annals of allergy.
[32] P. Marrack,et al. Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.
[33] M. Kronenberg,et al. Vα14i NKT Cells Are Innate Lymphocytes That Participate in the Immune Response to Diverse Microbes , 2005, Journal of Clinical Immunology.
[34] D. Katz,et al. Hapten-specific IgE antibody responses in mice. I. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. , 1973 .
[35] R. Mumper,et al. Nanotemplate Engineering of Cell Specific Nanoparticles , 2003 .
[36] Lili Qin,et al. The use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune response. , 2011, Biomaterials.
[37] Zoraida P. Aguilar,et al. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood‐stage human malaria vaccine , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] T. Kündig,et al. Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.
[39] Dan Peer,et al. Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.
[40] Jianlin Shi,et al. Hollow‐Structured Mesoporous Materials: Chemical Synthesis, Functionalization and Applications , 2014, Advanced materials.
[41] Haitao Jiang,et al. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. , 2012, International journal of pharmaceutics.
[42] Sudipta Seal,et al. Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. , 2009, ACS nano.
[43] Y. Bando,et al. Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment , 2017, Nature Communications.
[44] Xia Li,et al. Synergistic effects of stellated fibrous mesoporous silica and synthetic dsRNA analogues for cancer immunotherapy. , 2018, Chemical communications.
[45] S. Yoshino,et al. Adjuvant effect of zinc oxide on Th2 but not Th1 immune responses in mice , 2010, Immunopharmacology and immunotoxicology.
[46] I. Toth,et al. Modern Subunit Vaccines: Development, Components, and Research Opportunities , 2013, ChemMedChem.
[47] Agula Bo,et al. Magnesium sulfate induced toxicity in vitro in AGS gastric adenocarcinoma cells and in vivo in mouse gastric mucosa. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[48] A. Oyane,et al. Effect of coprecipitation temperature on the properties and activity of fibroblast growth factor-2 apatite composite layer , 2009 .
[49] Kenneth J. Dart,et al. Adjuvanticity and toxicity of cobalt oxide nanoparticles as an alternative vaccine adjuvant. , 2012, Nanomedicine.
[50] Daejin Kim,et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. , 2012, Angewandte Chemie.
[51] S. Kaufmann,et al. Challenges and responses in human vaccine development. , 2014, Current opinion in immunology.
[52] Byeong-Cheol Ahn,et al. Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence , 2016 .
[53] A. Taniguchi,et al. Mesoporous Caged‐γ‐AlOOH‐Double‐Stranded RNA Analog Complexes for Cancer Immunotherapy , 2018 .
[54] J L Pedraz,et al. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.
[55] Jianlin Shi,et al. In Vivo Bio‐Safety Evaluations and Diagnostic/Therapeutic Applications of Chemically Designed Mesoporous Silica Nanoparticles , 2013, Advanced materials.
[56] O. Finn. The dawn of vaccines for cancer prevention , 2017, Nature Reviews Immunology.
[57] Dmitri Golberg,et al. Boron nitride nanotubes functionalized with mesoporous silica for intracellular delivery of chemotherapy drugs. , 2013, Chemical communications.
[58] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[59] C. Coban,et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. , 2011, Immunity.
[60] Xia Li,et al. Rod-shaped and fluorine-substituted hydroxyapatite free of molecular immunopotentiators stimulates anti-cancer immunity in vivo. , 2016, Chemical communications.
[61] A. Harandi,et al. Vaccine adjuvants: scientific challenges and strategic initiatives , 2009, Expert review of vaccines.
[62] María Vallet-Regí,et al. Mesoporous materials for drug delivery. , 2007, Angewandte Chemie.
[63] P. Swider,et al. Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/beta-tricalcium phosphate porous ceramics. , 2009, Journal of biomedical materials research. Part B, Applied biomaterials.
[64] T. Roger,et al. Basic Calcium Phosphate Crystals Induce Monocyte/Macrophage IL-1β Secretion through the NLRP3 Inflammasome In Vitro , 2011, The Journal of Immunology.
[65] Gareth R. Williams,et al. Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry , 2014, The Journal of experimental medicine.
[66] L. Ruff,et al. Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody , 2012, Advanced materials.
[67] Vasso Apostolopoulos,et al. Pathogen recognition and development of particulate vaccines: does size matter? , 2006, Methods.
[68] Jian Liang,et al. Preparation of mesoporous calcium doped silica spheres with narrow size dispersion and their drug loading and degradation behavior , 2007 .
[69] J. Coote,et al. Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity☆ , 2014, Vaccine.
[70] J. Gutiérrez,et al. Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom , 2014, Journal of immunotoxicology.
[71] J. Tschopp,et al. Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.
[72] I. Melero,et al. Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.
[73] K. Hidajat,et al. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions. , 2005, Langmuir : the ACS journal of surfaces and colloids.
[74] J. Yewdell. Designing CD8+ T cell vaccines: it's not rocket science (yet). , 2010, Current opinion in immunology.
[75] Meiying Wang,et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. , 2013, ACS nano.
[76] Bin Wu,et al. The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant. , 2014, Biomaterials.
[77] Chengtie Wu,et al. Nanoporous microstructures mediate osteogenesis by modulating the osteo-immune response of macrophages. , 2017, Nanoscale.
[78] M. Jaroniec,et al. Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. , 2006, Small.
[79] Richard A. Flavell,et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.
[80] T. Hashimoto,et al. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma , 2013, Radiation Oncology.
[81] D. Ciocca,et al. A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients , 2007, Cell stress & chaperones.
[82] C. Traube,et al. Immunotherapy with a calcium phosphate‐adsorbed five‐grass‐pollen extract in seasonal rhinoconjunctivitis: a double‐blind, placebo‐controlled study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[83] Bengt Fadeel,et al. Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. , 2009, Toxicology and applied pharmacology.
[84] M. Aronova,et al. DNA-inorganic hybrid nanovaccine for cancer immunotherapy. , 2016, Nanoscale.
[85] Katrin Schwarz,et al. Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.
[86] P. Kupelian,et al. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[87] A. Punnoose,et al. The Influences of Cell Type and ZnO Nanoparticle Size on Immune Cell Cytotoxicity and Cytokine Induction , 2009, Nanoscale research letters.
[88] T. Ohno,et al. Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy , 2016, Advanced healthcare materials.
[89] D. Chaplin. Overview of the immune response. , 2003, The Journal of allergy and clinical immunology.
[90] Huizhi Guo,et al. Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein , 2012, Virology Journal.
[91] J. Blattman,et al. Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.
[92] Soumen Das,et al. Immunomodulation and T Helper TH1/TH2 Response Polarization by CeO2 and TiO2 Nanoparticles , 2013, PloS one.
[93] Min Zhu,et al. Mesoporous silica nanoparticles for enhancing the delivery efficiency of immunostimulatory DNA drugs. , 2014, Dalton transactions.
[94] Youngjin Choi,et al. The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. , 2016, Biomaterials.
[95] K. Schwarz,et al. Long‐lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation , 2006, European journal of immunology.
[96] T. Morcol,et al. Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection against Herpes Simplex Virus Type 2 , 2002, Clinical and Vaccine Immunology.
[97] Derek T. O'Hagan,et al. Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.
[98] Youngjin Choi,et al. Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.
[99] M. Guenounou,et al. Importance of hydroxyapatite particles characteristics on cytokines production by human monocytes in vitro. , 2003, Biomaterials.
[100] Huiying Zhu,et al. Europium-doped mesoporous silica nanosphere as an immune-modulating osteogenesis/angiogenesis agent. , 2017, Biomaterials.
[101] L. Peek,et al. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. , 2007, Journal of pharmaceutical sciences.
[102] F. Baneyx,et al. Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[103] T. Ohno,et al. Pore size-dependent immunogenic activity of mesoporous silica-based adjuvants in cancer immunotherapy. , 2014, Journal of biomedical materials research. Part A.
[104] Sudipta Seal,et al. Anti-inflammatory properties of cerium oxide nanoparticles. , 2009, Small.
[105] D. Dormont,et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. , 2004, Vaccine.
[106] Chengzhong Yu,et al. Understanding the Effect of Surface Chemistry of Mesoporous Silica Nanorods on Their Vaccine Adjuvant Potency , 2017, Advanced healthcare materials.
[107] J. Tschopp,et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.
[108] K. Onuma,et al. Mesoporous Silica‐Calcium Phosphate‐Tuberculin Purified Protein Derivative Composites as an Effective Adjuvant for Cancer Immunotherapy , 2013, Advanced healthcare materials.
[109] Henk C. Hoogsteden,et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.
[110] Jun Jiao,et al. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.
[111] Mariagrazia Pizza,et al. The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 , 2008, The Journal of Immunology.
[112] Rino Rappuoli,et al. Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.
[113] Maria Strømme,et al. Mesoporous silica particles induce size dependent effects on human dendritic cells. , 2007, Nano letters.
[114] T. Ohno,et al. Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. , 2016, Angewandte Chemie.
[115] A. Jarzab,et al. [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants]. , 2013, Postepy higieny i medycyny doswiadczalnej.
[116] M. Ferrari,et al. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. , 2015, Cell reports.
[117] K. Onuma,et al. Mesoporous bioactive glass coatings on stainless steel for enhanced cell activity, cytoskeletal organization and AsMg immobilization , 2010 .
[118] Jie Zheng,et al. Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. , 2013, Journal of the American Chemical Society.
[119] A. Godec,et al. Understanding controlled drug release from mesoporous silicates: theory and experiment. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[120] Young Keun Kim,et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. , 2011, Nature nanotechnology.
[121] D. Fearon,et al. Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.
[122] Jiye Shi,et al. One‐Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy , 2016, Advanced materials.
[123] Jeffrey B Ulmer,et al. Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.
[124] W. Li,et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. , 2012, Nano letters.
[125] Hong-mei Xu. Th1 cytokine-based immunotherapy for cancer. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.
[126] T. Morcol,et al. Calcium Phosphate Nanoparticle Adjuvant , 2000, Clinical Diagnostic Laboratory Immunology.
[127] D. Schrump,et al. Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins. , 2016, Cell chemical biology.
[128] A. Prasad,et al. Serum thymulin in human zinc deficiency. , 1988, The Journal of clinical investigation.
[129] R. Drezek,et al. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. , 2015, Small.
[130] Y. Yoshioka,et al. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. , 2010, Biomaterials.
[131] Rogério Gaspar,et al. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking , 2014, Front. Chem..
[132] K. Knutson,et al. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[133] Takafumi Ninomiya,et al. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. , 2013, ACS nano.
[134] H. Nauwynck,et al. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges , 2012, Expert review of vaccines.
[135] K. Onuma,et al. Zn- and Mg- Containing Tricalcium Phosphates-Based Adjuvants for Cancer Immunotherapy , 2013, Scientific Reports.
[136] G. R. Reddy,et al. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. , 2009, Veterinary microbiology.
[137] Mithat Gönen,et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.
[138] A. Balato,et al. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. , 2009, The Journal of investigative dermatology.
[139] Ennio De Gregorio,et al. The path to a successful vaccine adjuvant--'the long and winding road'. , 2009, Drug discovery today.
[140] B. Yvonnet,et al. Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen , 1986, Infection and immunity.
[141] Xia Li,et al. Biodegradable Metal Ion-Doped Mesoporous Silica Nanospheres Stimulate Anticancer Th1 Immune Response in Vivo. , 2017, ACS applied materials & interfaces.
[142] Jie Li,et al. Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.
[143] M. Guenounou,et al. Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. , 2007, Biomaterials.
[144] Y. Sogo,et al. Simple synthesis route of mesoporous AlOOH nanofibers to enhance immune responses , 2013 .
[145] C. J. Clements,et al. The global impact of vaccines containing aluminium adjuvants. , 2002, Vaccine.
[146] Dong Chen,et al. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. , 2010, Biomaterials.
[147] Jeffrey A. Hubbell,et al. Materials engineering for immunomodulation , 2009, Nature.
[148] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[149] XinRan Li,et al. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[150] J. Sprent,et al. T Cell Death and Memory , 2001, Science.
[151] A. Oyane,et al. Ascorbate-apatite composite and ascorbate-FGF-2-apatite composite layers formed on external fixation rods and their effects on cell activity in vitro. , 2009, Acta Biomaterialia.
[152] Ping Zhang,et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.
[153] S. Gabrielsson,et al. Adjuvant properties of mesoporous silica particles tune the development of effector T cells. , 2012, Small.
[154] Parul Gupta,et al. ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. , 2014, Toxicology letters.
[155] T. Ohno,et al. Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. , 2016, Colloids and surfaces. B, Biointerfaces.
[156] J. Mannhalter,et al. Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide. , 1999, Vaccine.
[157] K. Leong,et al. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. , 2012, Nature materials.
[158] S. Reed,et al. Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.
[159] M. Leslie. Solution to vaccine mystery starts to crystallize. , 2013, Science.
[160] R. Edelman. Survey of human-use adjuvants , 2003, Expert review of vaccines.
[161] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[162] P. Minor. Live attenuated vaccines: Historical successes and current challenges. , 2015, Virology.
[163] Mithat Gönen,et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe , 2014, Science Translational Medicine.
[164] Yanli Zhao,et al. Multifunctional Mesoporous Silica Nanoparticles for Cancer‐Targeted and Controlled Drug Delivery , 2012 .
[165] Y. Sogo,et al. Hollow ZnO Nanospheres Enhance Anticancer Immunity by Promoting CD4+ and CD8+ T Cell Populations In Vivo. , 2017, Small.
[166] Lili Qin,et al. Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles. , 2010, Biomaterials.
[167] Lin Zeng,et al. The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. , 2011, Biomaterials.
[168] R. Rappuoli,et al. Vaccinology at the beginning of the 21st century , 2005, Current Opinion in Immunology.
[169] M. Morlock,et al. Proinflammatory and osteoclastogenic effects of beta-tricalciumphosphate and hydroxyapatite particles on human mononuclear cells in vitro. , 2009, Biomaterials.
[170] N. Mantis,et al. Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. , 1999, Vaccine.
[171] W. Wu,et al. Mechanisms of adjuvancy: I--Metal oxides as adjuvants. , 1997, Vaccine.
[172] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[173] K. Ishii,et al. Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant. , 2016, Vaccine.
[174] R. Bomford. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bord , 1980, Clinical and experimental immunology.
[175] T. Ohno,et al. Hollow Structure Improved Anti-Cancer Immunity of Mesoporous Silica Nanospheres In Vivo. , 2016, Small.
[176] M. Guenounou,et al. Influence of the zinc concentration of sol-gel derived zinc substituted hydroxyapatite on cytokine production by human monocytes in vitro. , 2006, Biomaterials.
[177] T. Deerinck,et al. Quantum Dots for Tracking Dendritic Cells and Priming an Immune Response In Vitro and In Vivo , 2008, PloS one.
[178] Yufang Zhu,et al. Binding of CpG oligodeoxynucleotides to mesoporous silica nanoparticles for enhancing delivery efficiency , 2015 .
[179] H. Aggerbeck,et al. Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I. , 1995, Vaccine.
[180] V E Schijns,et al. Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.
[181] T. Ohno,et al. Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. , 2013, Acta biomaterialia.
[182] E. B. Lindblad. Aluminium compounds for use in vaccines , 2004, Immunology and cell biology.
[183] Y. Liu,et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. , 2009, Biomaterials.
[184] C. Coban,et al. DNA released from dying host cells mediates aluminum adjuvant activity , 2011, Nature Medicine.
[185] A. Taniguchi,et al. Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy , 2017, Scientific Reports.